Does vitamin E prevent gentamicin-induced ototoxicity?

Area of Science:

• Otolaryngology
• Pharmacology
• Clinical Medicine

Background:

• Aminoglycoside antibiotics, such as gentamicin, are crucial for treating acute pulmonary infections.
• Aminoglycoside therapy can lead to ototoxicity, characterized by hearing loss.
• Vitamin E is an antioxidant with potential protective properties against drug-induced toxicity.

Purpose of the Study:

• To evaluate the protective efficacy of vitamin E against aminoglycoside-induced ototoxicity.
• To determine if vitamin E supplementation can prevent hearing damage in patients undergoing gentamicin therapy.

Main Methods:

• A randomized, double-blind, placebo-controlled study.
• 52 patients receiving gentamicin (240 mg/day) for acute pulmonary infections were enrolled.
• Participants were randomly assigned to receive either vitamin E (2800 mg/day) or a placebo for 7 days.
• Hearing function was assessed before treatment and 6-8 weeks post-treatment.

Main Results:

• Hearing function was evaluated by measuring auditory thresholds.
• An increase in auditory thresholds was observed in a similar proportion of patients in both the vitamin E and placebo groups.
• No statistically significant difference in the incidence or severity of ototoxicity was found between the two groups.

Conclusions:

• Vitamin E supplementation did not demonstrate a protective effect against gentamicin-induced ototoxicity.
• The study failed to confirm any protective action of vitamin E in preventing hearing loss associated with gentamicin therapy.